Fundamentals of Geriatric Pharmacotherapy

Total Page:16

File Type:pdf, Size:1020Kb

Fundamentals of Geriatric Pharmacotherapy Index ADRs. See Adverse drug reactions Adrenergics, 419 A Adrenocorticotropic hormone, 278 Abciximab, 168 Adult day centers, 11 Abdominal assessment, 81 Adult Protective Services, 41 Absorption, age-related changes in, 68 Advance directives, 37–39, 77, 94–95 Abuse, elderly, 41 ADVANCE trial, 271 Acamprosate, 401 Adverse drug events (ADEs), 105–106, 110–112, Acarbose, 261, 267 116–117 diarrhea and, 312 medication sensitivity and, 68–69 Access-A-Ride, 96 opportunities to improve drug use and, 113–115 ACCORD trial, 270–271 reduction in, 112–113 ACCORD BP trial, 162–163 therapeutic failure and, 112 ® Accu-Check Compact , 270 transitions in care and, 118 ACE inhibitors. See Angiotensin-converting enzyme Adverse drug reaction (ADR), 105–106, inhibitors 110–111 Acetaminophen, 110, 301, 425–426, 430, 444–447 Adverse drug withdrawal events (ADWEs), 105–106, heart failure and, 177 111–112 in hospice and palliative care, 134 Advisory Committee on Immunization Practices terminally ill and, 133 (ACIP), 488, 490–491 Acetazolamide, 420 ADWEs. See Adverse drug withdrawal events Acetylcholinesterase inhibitor(s), 230, 237–238, 312, Affordable Care Act (ACA), 46–47 356 African American culture, 35, 39 Acrylic dressings, 464 Age, 4–5 Activities of daily living (ADLs), 8, 10–11, 77, 92, 341 Age strata, 5 Actos, 261 Agency for Healthcare Research and Quality, 344 Acute care, 10 Age-related changes, 74 Acute Care for Elders (ACE) units, 12 Age-Related Eye Disease Research Group, 421 Acute coronary syndromes, 167–170 Age-Related Eye Disease Study, 422–423 Acute pain, 424 Age-related macular degeneration, 421 ADAGIO trial, 351 Aging theories, 58–59 Adaptive immunity, 515, 516, 517 Agitation, 13, 142–143, 342–343 ADEs. See Adverse drug events Albuterol, 142, 202, 211, 218, 540 Adenosylmethionine (SAMe), 445 Alcohol abuse/alcoholism/use, 94, 396–398, 447, ADLs. See Activities of daily living 485–486, 530 Administration on Aging, 10 binge drinking, 177 Unauthenticated | Downloaded 10/02/21 03:39 AM UTC 546 | Fundamentals of Geriatric Pharmacotherapy delirium and, 345 American Geriatrics Society, 9, 107, 268, 426, 441, dysphagia and, 299 443, 497, 525 insomnia and, 381 Panel on Improving Care for Elders with withdrawal, anxiety and, 381 Diabetes, 260 Alcohol Use Disorders Identification Test (AUDIT), 398 Panel on the Pharmacological Management of Aldosterone antagonists, 173, 174, 176 Persistent Pain, 133 Alendronate, 449, 451, 453, 454, 455 American Heart Association, 161–163, 171–172, 177, ALF. See Assisted living facility 183, 225, 295–296 Alfuzosin, 234, 244, 245 physical activity guidelines, 93 Alginates, 462, 464 American Medical Association, 39 Alli, 262 American Pain Society, 425 Alogliptin, 268 American Red Cross, 18 Alpha agonists, hypertension and, 163 American Society of Consultant Pharmacists, 8 Alpha-1 adrenergic blockers, 164, 174 American Society for Nutrition, 272 Alpha-adrenergic agonists, 233, 243, 419–420 American Stroke Association, 172, 183 Alpha-adrenergic blockers/antagonists, 243–245 American Thoracic Society, 212, 529, 531 pharmacodynamic changes, recommendations American Urological Association, 232, 243 for, 71 Benign prostatic hyperplasia symptom score, Alpha-antagonists, hypertension and, 163 240 Alpha-glucosidase inhibitors, 263–264, 267 Symptom Index (AUA–SI), 239, 241–242, 243 Alpha-receptor agonist, 160 Aminoglycosides, 419 Alpha-receptor antagonist, 159 distribution and, 68 Alprazolam, 402 hearing loss and, 63 Alteplase, 168 Amiodarone, 228 Altered taste, 293, 295 altered taste and, 295 Altered vision, 6 atrial fibrillation and, 178 Alternative medicine, 36 dementia and, 335 Alvimopan, 309 hypothyroidism and, 275–276 Alzheimer disease, 461, 487 Amitriptyline central nervous system issues and, 337–341, central nervous system issues and, 351 344, 360 as high-risk medication, 107 TSH concentrations and, 275 pain/sensory issues and, 426–427, 429, 434 Alzheimer’s Disease Assessment Scale– Amobarbital, high-risk medication, 107 cognitive subscale (ADAS–cog), 89 Amoxicillin, 295 Alzheimer’s Disease Cooperative Study ADL (ADCS– Amoxicillin/clavulanate, 523 ADL) Inventory, 92 Amoxicillin/clavulanate plus macrolide, 523 Amantadine, 350, 490, 532 Amphetamine, toxicity, 295 Amaryl, 261 Ampicillin, 523 American Academy of Family Physicians, 340 Ampicillin/sulbactam plus macrolide, 523 American Academy of Neurology, 349, 351–352, 356 Amylin analog, 264, 267 American Academy of Pain Medicine, 425 Analgesics, 228, 345 American Association of Clinical Endocrinologists, Anastrozole, 455 449 Androgel, 282 American Association of Retired Persons (AARP), 4 Androgens, 282–283 American Board of Internal Medicine Foundation, 497 Andropause, 279–280 American Cancer Society, 81, 494–497, 500 Anemia, 480–488 American College of Cardiology, 161–163, 171–172, case, 502–503 177, 225 of chronic disease, 484 American College of Chest Physicians, 171, 177, of chronic inflammation/kidney disease, 482 185–187 of chronic kidney disease, 484, 486–487 American College of Gastroenterology, 303 of inflammation, 484, 486–487 American College of Physicians, 340 Angiotensin-converting enzyme (ACE) inhibitor(s), American College of Rheumatology, 444, 456–457 110, 225, 228 American Dental Association, 295 adverse drug withdrawal event and, 111 American Diabetes Association, 259, 260, 268 arginine vasopressin (ADH) and, 227–228 American Epilepsy Society, 356 chronic kidney disease and, 225 coronary events and, 168–169 Unauthenticated | Downloaded 10/02/21 03:39 AM UTC Index | 547 diarrhea and, 312 tapering of, 114 heart failure and, 173–176 withdrawal and, 131 hypertension and, 161–163 Antidiabetics pharmacodynamic changes, recommendations delirium and, 345 for, 71 See also specific antidiabetics pharmacotherapy of, 162–164, 168–170, Anti-diuretic hormone (ADH), 221, 227–228 173–176 Antiepileptics, 184, 425–426 stress incontinence and, 230 drug-disease interactions, 365–366 Angiotensin II receptor blockers, 164 Antihistamines, 140, 243, 394, 305 Angiotensin receptor blockers (ARBs), 225 Antihypertensives, 466 hypertension and, 161, 163 Antimicrobials Anorexia, 139, 141 delirium and, 345 Antacids, 447, 301 dressings, 465 Anti-aging strategies, 65–66 Antimicrobial stewardship, 515, 519 Anti-allergen, 206 Antineoplastics, 228 Antibiogram, 515, 518 diarrhea and, 312 Antibiotic stewardship, 519, 521 Antioxidants Antibiotics, 463, 517–518, 520, 530. See also specific supplements, 421 antibiotics therapy, anti-aging and, 65 Anticholinergics, 305, 310, 419, 528 Antiparkinson medications, 111–113, 228 anxiety and, 381 Antiplatelet agents/therapy, 110, 296, 447 chronic obstructive pulmonary disease and, GERD and, 304 207–208 underuse of, 109 delirium and, 345 Antipsychotics, 344, 419, 466 drug-disease interactions of, 107–108 adverse drug withdrawal events and, 111 dysphagia and, 297 agitation and, 143 functional decline and, 66 delirium and, 348 inhaled bronchodilators and, 200, 202, 211 distribution and, 69 insomnia and, 381 drug-disease interactions by, 108 nausea/vomiting and, 140, 305 dysphagia and, 297 overflow incontinence and, 231 falls and, 441 pharmacodynamic changes, recommendations functional decline and, 66 for, 71 GERD and, 303 terminal secretions and, 143 hyperglycemia and, 288 urinary retention and, 230 pharmacodynamic changes, recommendations, Anticoagulants, 110, 296, 447 71 adverse drug reactions and, 111 renal/urologic disorders and, 228, 243 diabetes and, 269 Antispasmodics, 308 Anticonvulsants, 214, 228, 427, 455 Antithrombotic therapy, 110, 157, 171 delirium and, 345 Antithrombotic Trialists’ Collaboration, 171, 184 dementia and, 335 Anti-tumor necrosis factor (TNF)–alpha, 213, 457–458 depression and, 381 Anti-vascular endothelial growth factor, 421 diarrhea and, 312 Anxiety, 137–138, 385–392 dosing of, 71 diagnostic criteria for, 387–388 drug-disease interactions of, 107, 108 Apixaban, 179–180, 182 dying patient and, 133 Apomorphine, 350, 351, 354 endocrine disorders and, 271, 282 Apoptosis, 59 falls and, 441 Appetite stimulants, 184 tapering of, 114 Apraclonidine, 420 Antidepressants, 184, 425 Aprepitant, 306 adverse drug withdrawal events and, 111–112 Aranesp, 487 anxiety and, 381 ARBs. See Angiotensin receptor blockers falls and, 441 Area Agencies on Aging, 19 insomnia and, 381 Arginine vasopressin (AVP), 221, 227–228 psychiatric disorders and, 381–382, 402 Aricept, 340 renal/urologic disorders and, 228, 243 Aripiprazole, 348 Unauthenticated | Downloaded 10/02/21 03:39 AM UTC 548 | Fundamentals of Geriatric Pharmacotherapy ARISTOTLE trial, 180 dysphagia and, 297 Armour thyroid, 262 Bariatric surgery, 273 Aromatase inhibitors, 282 Beclomethasone dipropionate, 203 Artificial nutrition, 39 Bedrails, 442 Asal, Nicole J., 221–256 Bedside assessment, 82–83 Ascorbic acid, 485 Beers criteria, 107 Aspiration pneumonia, 293, 294, 298–299, 529–530 central nervous system and, 342, 353–354 Aspirin, 110, 448, 499 pain/sensory disorders and, 428 antithrombotic therapy and, 170, 181 pharmacotherapy and, 175–176, 178, 180 bleeding and, 181 Behave-AD (Behavioral Pathology in Alzheimer’s frail elderly patient and, 54 Disease Rating Scale), 91 GERD and, 303 Behavioral therapy, 273 low dose, 260, 460 Belgeri, Myra T, 377–416 peripheral arterial disease and, 171–172 Belviq, 262 secondary prevention of coronary events with, Beneficence, 29, 30, 32 168, 169 Benign prostatic hyperplasia (BHP), 237–239, 522 STEMI, NSTEMI and, 168 dietary supplements and, 246–247 stopping, 131 surgery for, 247 stroke prevention, 178–179, 183–185 Benzodiazepine-receptor agonists, 394–395,
Recommended publications
  • Pharmacy Prior Authorization Non-Formulary and Prior
    Pharmacy Prior Authorization Non-Formulary and Prior Authorization Guidelines Scroll down to see PA Criteria by drug class, or Ctrl+F to search document by drug name PA Guideline Requirements Duration of Approval if Requirements Are Met Non-Formulary Requests for Non-Formulary Medications that do not have specific Prior Authorization Initial Approval: Medication Guidelines will be reviewed based on the following: • Minimum of 3 months, Guideline • An appropriate diagnosis/indication for the requested medication, depending on the • An appropriate dose of medication based on age and indication, diagnosis, to determine • Documented trial of 2 formulary agents for an adequate duration have not been effective or adherence, efficacy and tolerated patient safety monitoring OR • All other formulary medications are contraindicated based on the patient’s diagnosis, other Renewal: medical conditions or other medication therapy, • Minimum of 6 months OR • Maintenance medications • There are no other medications available on the formulary to treat the patient’s condition may be approved Indefinite Maryland Physicians Care determines patient medication trials and adherence by a review of pharmacy claims data over the preceding twelve months. Additional information may be requested on a case-by-case basis to allow for proper review. Medications Requests for Medications requiring Prior Authorization (PA) will be reviewed based on the PA As documented in the requiring Prior Guidelines/Criteria for that medication. Scroll down to view the PA Guidelines for specific individual guideline Authorization medications. Medications that do not have a specific PA guideline will follow the Non-Formulary Medication Guideline. Additional information may be required on a case-by-case basis to allow for adequate review.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Does Your Patient Have Bile Acid Malabsorption?
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 Carol Rees Parrish, MS, RDN, Series Editor Does Your Patient Have Bile Acid Malabsorption? John K. DiBaise Bile acid malabsorption is a common but underrecognized cause of chronic watery diarrhea, resulting in an incorrect diagnosis in many patients and interfering and delaying proper treatment. In this review, the synthesis, enterohepatic circulation, and function of bile acids are briefly reviewed followed by a discussion of bile acid malabsorption. Diagnostic and treatment options are also provided. INTRODUCTION n 1967, diarrhea caused by bile acids was We will first describe bile acid synthesis and first recognized and described as cholerhetic enterohepatic circulation, followed by a discussion (‘promoting bile secretion by the liver’) of disorders causing bile acid malabsorption I 1 enteropathy. Despite more than 50 years since (BAM) including their diagnosis and treatment. the initial report, bile acid diarrhea remains an underrecognized and underappreciated cause of Bile Acid Synthesis chronic diarrhea. One report found that only 6% Bile acids are produced in the liver as end products of of British gastroenterologists investigate for bile cholesterol metabolism. Bile acid synthesis occurs acid malabsorption (BAM) as part of the first-line by two pathways: the classical (neutral) pathway testing in patients with chronic diarrhea, while 61% via microsomal cholesterol 7α-hydroxylase consider the diagnosis only in selected patients (CYP7A1), or the alternative (acidic) pathway via or not at all.2 As a consequence, many patients mitochondrial sterol 27-hydroxylase (CYP27A1). are diagnosed with other causes of diarrhea or The classical pathway, which is responsible for are considered to have irritable bowel syndrome 90-95% of bile acid synthesis in humans, begins (IBS) or functional diarrhea by exclusion, thereby with 7α-hydroxylation of cholesterol catalyzed interfering with and delaying proper treatment.
    [Show full text]
  • Drugs That Require Prior Authorization
    Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your HMSA Akamai Advantage (PPO) plan before filling prescriptions for the drugs shown in the chart below. The HMSA Akamai Advantage plan will only provide coverage after it determines that the drug is being prescribed according to the criteria specified in the chart. You, your appointed representative, or your prescriber can request prior authorization by calling HMSA at 1 (855) 479-3659, 24 hours a day, 7 days a week. Customer service is available in English and other languages. TTY/TDD users should call 711. PA Criteria Prior Authorization Group ACITRETIN Drug Names ACITRETIN, SORIATANE Covered Uses All FDA-approved indications not otherwise excluded from Part D, prevention of non-melanoma skin cancers in high risk individuals. Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions Coverage Duration Plan Year Other Criteria Prior Authorization Group ACTEMRA Drug Names ACTEMRA Covered Uses All FDA-approved indications not otherwise excluded from Part D, unicentric Castleman's disease, multicentric Castleman's disease. Exclusion Criteria Required Medical Information For moderately to severely active rheumatoid arthritis (new starts only): Inadequate response, intolerance or contraindication to a self-injectable tumor necrosis factor (TNF) inhibitor (e.g., adalimumab) or a targeted synthetic disease-modifying antirheumatic drug (DMARD) (e.g., tofacitinib). For active polyarticular juvenile idiopathic arthritis (new starts only): Inadequate response, intolerance or contraindication to a TNF inhibitor (e.g., adalimumab). For active systemic juvenile idiopathic arthritis (new starts only): Inadequate response to a corticosteroid monotherapy, methotrexate or leflunomide. Age Restrictions Prescriber Restrictions Coverage Duration Plan Year Other Criteria Prior Authorization Group ACTHAR HP Drug Names H.P.
    [Show full text]
  • FYCOMPA® • Severe Hepatic Impairment: Not Recommended (2.4) ® Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION mg (mild) and 4 mg (moderate) once daily at bedtime (2.4) ® These highlights do not include all the information needed to use FYCOMPA • Severe Hepatic Impairment: Not recommended (2.4) ® safely and effectively. See full prescribing information for FYCOMPA . • Severe Renal Impairment or on Hemodialysis: Not recommended (2.5) ® • Elderly: Increase dose no more frequently than every 2 weeks (2.6) FYCOMPA (perampanel) tablets, for oral use, CIII FYCOMPA® (perampanel) oral suspension, CIII ----------------------DOSAGE FORMS AND STRENGTHS-----------------­ Initial U.S. Approval: 2012 • Tablets: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg (3) WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Oral Suspension: 0.5 mg/mL (3) See full prescribing information for complete boxed warning. ----------------------------------CONTRAINDICATIONS----------------------­ None (4) • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation -----------------------WARNINGS AND PRECAUTIONS--------------------­ and threats have been reported in patients taking FYCOMPA (5.1) • Suicidal Behavior and Ideation: Monitor for suicidal thoughts or • Monitor patients for these reactions as well as for changes in mood, behavior (5.2) behavior, or personality that are not typical for the patient, particularly • Neurologic Effects: Monitor for dizziness, gait disturbance, somnolence, during the titration period and at higher doses (5.1) and fatigue
    [Show full text]
  • "Bouncy Gait" in Lance-Adams Syndrome with Perampanel
    Open Access Case Report DOI: 10.7759/cureus.6773 Improvement of "Bouncy Gait" in Lance-Adams Syndrome with Perampanel Shen-Yang Lim 1 , Dushyanth Babu Jasti 2 , Ai Huey Tan 1 1. Division of Neurology and the Mah Pooi Soo & Tan Chin Nam Centre for Parkinson’s & Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, MYS 2. Division of Neurology, Kasturba Medical College, Manipal, IND Corresponding author: Shen-Yang Lim, [email protected] Abstract Lance-Adams syndrome (LAS) is chronic post-hypoxic myoclonus that is often associated with sudden lapses in muscle tone (negative myoclonus) in the legs, causing a disabling "bouncy gait." Given its relative rarity, there are no controlled treatment studies of LAS. The majority of cases require polypharmacy management, with an incomplete response. "Bouncy gait," in particular, is notoriously medication-refractory. Here, we report a patient with long-standing LAS who improved markedly when low-dose perampanel was added to his existing treatment regime consisting of clonazepam, levetiracetam, sodium valproate, and acetazolamide. Categories: Internal Medicine, Neurology, Physical Medicine & Rehabilitation Keywords: lance-adams syndrome, perampanel, myoclonus, negative myoclonus, bouncy gait Introduction Lance-Adams syndrome (LAS) is chronic post-hypoxic myoclonus with onset days to weeks after a hypoxic episode, when the patient has regained consciousness [1]. The myoclonus is typically multifocal, worse with action, and associated with sudden lapses in muscle tone in the legs, causing a "bouncy gait" [1]. Additional features may include cognitive impairment, seizures, dysarthria, and ataxia [1]. Given its relative rarity, there are no controlled treatment studies of LAS. The majority of cases require polypharmacy management, with an incomplete response.
    [Show full text]
  • BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18
    Oregon Board of Pharmacy BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18 The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs. Wednesday, June 6, 2018 @ 8:30AM – Conference Rm A Thursday, June 7, 2018 @ 8:30AM – Conference Room A ≈ If special accommodations are needed for you to attend or participate in this Board Meeting, please contact Loretta Glenn at: (971) 673-0001. ≈ WEDNESDAY, JUNE 6, 2018 I. 8:30AM OPEN SESSION, Penny Reher, R.Ph, Presiding A. Roll Call B. Agenda Review and Approval Action Necessary II. Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public III. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k). A. Items for Consideration and Discussion: 1. Deliberation on Disciplinary Cases and Investigations 2. Personal Appearances 3. Deficiency Notifications 4. Case Review B. Employee Performance Review pursuant to ORS 192.660(2)(i). IV. OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin some of the following scheduled agenda items - time permitting at approximately 3:30PM. V. Approve Consent Agenda* Action Necessary *Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion.
    [Show full text]
  • Major Products
    Data Section Major Products Innovative Pharmaceuticals Business Innovative Pharmaceuticals Business Brand Name (Generic Name) Efficacy Launched Remarks Brand Name (Generic Name) Efficacy Launched Remarks Japan [Daiichi Sankyo Co., Ltd.] US [Daiichi Sankyo Inc.] A first combination drug of the DPP-4 inhibitor teneligliptin and the SGLT2 inhibitor Opioid-induced First once-daily oral product approved by the FDA for the treatment of opioid-induced (teneligliptin / Type 2 diabetes mellitus MOVANTIK (naloxegol) 2015 CANALIA 2017 canagliflozin approved in Japan, which demonstrates blood glucose-lowering activity constipation treatment constipation (OIC) for adults with chronic non-cancer pain. canagliflozin) treatment through a complementary pharmacological effect. Orally active Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications to Sodium channel blocker. Suppresses the excessive excitation of nerves in the brain, and VIMPAT (lacosamide) Anti-epileptic agent 2016 SAVAYSA (edoxaban) Anticoagulant 2015 reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial reduces the occurrence of epileptic seizures. fibrillation (NVAF) and for the treatment of venous thromboembolism (VTE) (deep vein ADP receptor inhibitor. Inhibits platelet aggregation and reduces the incidence of artery thrombosis (DVT) and pulmonary embolism (PE)). Efient (prasugrel) Antiplatelet agent 2014 stenosis and occlusion due to thrombosis. Effient (prasugrel) Antiplatelet agent 2009 Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion. Treatment for Benicar 2002 Benicar: Olmesartan osteoporosis / inhibitor Human monoclonal anti-RANKL antibody. Subcutaneous formulation which controls Benicar HCT 2003 Benicar HCT: A combination drug of olmesartan medoxomil and hydrochlorothiazide (diuretic) PRALIA (denosumab) for rheumatoid arthritis- 2013 bone resorption and bone destruction by specifically inhibiting RANKL.
    [Show full text]
  • Pdf4 Complex I and the Aryl Palladium Precursor II Underwent Sequential Single Electron Abstraction from Aryl Pd(II) Complex
    Design, synthesis, methodology development, and evaluation of PET imaging agents targeting cancer and CNS disorders By Gengyang Yuan B.S. in Chemical Engineering and Technology, Zhejiang University of Technology M.S. in Pharmaceutical Engineering, Zhejiang University A dissertation submitted to The Faculty of the College of Science of Northeastern University in partial fulfillment of the requirements for the degree of Doctor of Philosophy April 21, 2017 Dissertation directed by Michael P. Pollastri Associate Professor and Chair of Chemistry and Chemical Biology Co-directed by Neil Vasdev Adjunct Associate Professor of Chemsitry and Chemical Biology Associate Professor of Radiology, Massachusetts General Hospital and Harvard Medical School Dedication To my parents Zhijun and Yongmian and my wife Ran and daughter Isabella ii Acknowledgements This dissertation would not have been possible without the support, guidance and encouragement of numerous people who have helped me along the way. First and foremost, I would like to thank Northeastern University and the Department of Chemistry and Chemical Biology for supporting me to pursue my doctoral study. I would like to especially thank my current advisor Professor Michael Pollastri for helping me out when I needed it the most. I appreciate you for taking me into your group and giving me full support to finish my thesis projects. I also especially thank my co-advisor Professor Neil Vasdev for taking me into his group at Mass. General Hospital & Harvard Medical School and teaching me the PET radiochemistry and PET imaging. I could not image how I could accomplish this work without your help. I also got a lot of help from Dr.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Activation with Glutamate/NMDA Receptor Inhibition
    biomolecules Article − Amantadine Combines Astroglial System Xc Activation with Glutamate/NMDA Receptor Inhibition Tomosuke Nakano, Toshiki Hasegawa, Dai Suzuki, Eishi Motomura and Motohiro Okada * Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan; [email protected] (T.N.); [email protected] (T.H.); [email protected] (D.S.); [email protected] (E.M.) * Correspondence: [email protected]; Tel.: +81-59-231-5018 Received: 21 April 2019; Accepted: 15 May 2019; Published: 17 May 2019 Abstract: A glutamate/NMDA receptor (NMDA-R) antagonist, amantadine (AMA) exhibits a broad spectrum of clinically important properties, including antiviral, antiparkinsonian, neuroprotective, neuro-reparative and cognitive-enhancing effects. However, both clinical and pre-clinical studies have demonstrated that noncompetitive NMDA-R antagonists induce severe schizophrenia-like cognitive deficits. Therefore, this study aims to clarify the clinical discrepancy between AMA and noncompetitive NMDA-R antagonists by comparing the effects of AMA with those of a noncompetitive NMDA-R antagonist, MK801, on rat tripartite glutamatergic synaptic transmission using microdialysis and primary cultured astrocytes. Microdialysis study demonstrated that the stimulatory effects of AMA on L-glutamate release differed from those of MK801 in the globus pallidus, entorhinal cortex and entopeduncular nucleus. The stimulatory effect of AMA on L-glutamate release was modulated by activation of cystine/glutamate antiporter (Sxc). Primary cultured astrocytes study demonstrated that AMA also enhanced glutathione synthesis via Sxc activation. Furthermore, carbon-monoxide induced damage of the astroglial glutathione synthesis system was repaired by AMA but not MK801.
    [Show full text]